Lundquist Institute Investigator Dr. Eric Daar and Research Team Find HIV Patients Benefit from Ingestible Sensor Technology in HIV Treatment

Findings published in The Lancet Ebiomedicine demonstrate positive effect of next-generation ingestible sensor for HIV therapy

Ingestible Sensor Technology – Smart Pill

The study used a small edible sensor that is over-encapsulated along with the medication.  When ingested, it is detected by a patch with an integrated monitor and sensor worn by the patient.  The monitor sends a Bluetooth signal to a mobile device, which in turn sends an encrypted message to a central server that records, in real time, that a dose of medication has just been taken.

The study used a small edible sensor that is over-encapsulated along with the medication. When ingested, it is detected by a patch with an integrated monitor and sensor worn by the patient. The monitor sends a Bluetooth signal to a mobile device, which in turn sends an encrypted message to a central server that records, in real time, that a dose of medication has just been taken.

Torrance, Calif., Nov. 15, 2022 (GLOBE NEWSWIRE) — LOS ANGELES (November 15, 2022) – Dr. Eric Daar, a researcher at the Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, is the co -principal investigator for the $4 million National Institute of Mental Health grant that supported research that found that HIV patients whose drug regimen was monitored by an innovative ingestible sensor system were more adherent to antiretrovirals (ARVs) and, in turn, they experienced lower viral loads. The findings, “Ingestible Sensor System to Measure, Monitor, and Improve Adherence to Antiretroviral Therapy: A Randomized, Usual Care-Controlled, Open-Label Trial,” were published November 11 in The Ebiomedicine Lancet.

The team of investigators included researchers from UCLA, the Nebraska Medical Center, Yale University and Harvard University. The team assessed the feasibility, acceptability, and sustainability of using the Proteus Digital Health Feedback (PDHF) information technology system, assessed its accuracy, and assessed its effectiveness in monitoring and leveraging medication adherence. The published findings are an important step forward to measure and monitor medication adherence in HIV-AIDS patients and develop real-time interventions in a population that requires increased medical surveillance.

“When patients first enrolled in our study, they had problems with consistent adherence to their medications. During the course of the study, they often expressed that the ingestible sensor technology system provided them with the additional information and support they needed to successfully manage their HIV infection,” said Dr. Daar, Chief, Division of Medicine HIV at Harbor-UCLA Medical Center. and Professor of Medicine at the David Geffen School of Medicine at UCLA.

PDHF uses a tiny, edible sensor that is over-encapsulated along with the medication. When ingested, it is detected by a patch with an integrated monitor and sensor worn by the patient. The monitor sends a Bluetooth signal to a mobile device, which in turn sends an encrypted message to a central server that records, in real time, that a dose of medication has just been taken.

“After more than two decades of improving technology, ingestible sensor technology is, to date, the most advanced and accurate IT-based method for measuring and monitoring adherence behavior with wireless and real-time processes through from a mobile device,” said Dr. Honghu Liu, co-principal investigator of the study and chair of the Section of Public and Population Health at the UCLA School of Dentistry. “Our study delivered especially promising results for those who have significant challenges in adhering to antiretroviral medications.”

Press contact for the Lundquist Institute:

Max Benavidez, Ph.D. [email protected] 310-200-2682

Link to article: https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964%2822%2900512-6/full text

Attached file

CONTACT: Max Benavidez The Lundquist Institute for Biomedical Innovation 310-200-2682 [email protected]

Leave a Reply

Your email address will not be published. Required fields are marked *